Viewing Study NCT06637046



Ignite Creation Date: 2024-10-26 @ 3:42 PM
Last Modification Date: 2024-10-26 @ 3:42 PM
Study NCT ID: NCT06637046
Status: COMPLETED
Last Update Posted: None
First Post: 2024-10-07

Brief Title: Does Blood Vessel Vasodilation Caused by Focal Infiltration of Lidocaine Cause Temporary Nerve Functional Recovery for Patients with Common Peroneal Nerve Injury or Entrapment Testing the Phoenix Sign Effect Between Lidocaine a Common Local Anesthetic and Papaverine a Know Vasodilator
Sponsor: None
Organization: None

Study Overview

Official Title: Is the Phoenix Sign Phenomenon Due to Vasodilation a Double-Blinded Randomized Controlled Trial Comparing Motor Function Recovery After Diagnostic Common Fibular Nerve Block with Lidocaine and Papaverine
Status: COMPLETED
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical trial is to compare lidocaine without epinephrine to papaverine a known vasodilatory agent in creating improved motor strength in patients with drop foot involving an entrapment of the Common Peroneal Nerve This phenomenon has been named the Phoenix Sign and is a very specific peripheral nerve block

Researchers will compare the effects of the above agent for pre and post infiltration changes in motor strength

Participants will

Will be randomized to one of either agents already listed
After receiving the ultrasound guided injection motor testing will be evaluated in 4-6 minutes with manual motor strength testing of the anterior compartment muscles
No additional follow will be required
Detailed Description: A double-blinded randomised prospective controlled trial was conducted at US Neuropathy Centers in Marietta GA under the approval of the Kennesaw State University Institutional Review Board Patients with weak dorsiflexion of the ankle or a drop foot were recruited from the existing clinical practice at US Neuropathy Centers Cohort inclusion criteria also included a stable medical and medication status ages 18-85 speaking English as the primary language and ambulatory Walking aids or ankle-foot orthosis were permitted Based on the inclusion criteria only 20 patients were enrolled Patients were recruited over a period of 1 year and two months from January 2021 to March 2022 with no requirement for follow-up The enrolment phase was concluded as the study was originally designed as a pilot investigation with recruitment limited to a single small medical practice A total of 20 patients were successfully enrolled within this settingParticipants were randomised by the throw of dice to injection of 03 cc of Papaverine HCl 10 mgmL or 03 cc of 1 Lidocaine HCl adjacent to CFN in a room separate from patient room Injection solutions were prepared by non-blinded assistants and were visually indistinguishable Patients and physicians are blinded to drugs received Motor strength of the Extensor Hallucis Longus EHL Tibialis Anterior TA and Extensor Digitorum Longus EDL muscles were tested Strength was rated according to the Medical Research Council Manual Muscle Testing scale 0-5 The CFN at the fibular neck was identified under high-resolution ultrasound imaging The injection site was prepared with alcohol and ethyl chloride was used to anaesthetise the skin A 30-gauge 1-inch needle was inserted adjacent to but not within the CFN The infiltrate was delivered at the level of the fibular neck just proximal to where the CPN coursed beneath the deep fascia of the peroneus longus This was immediately adjacent to the first known anatomical site of compression of the CPN 03cc of the drug was delivered

The investigator then waited approximately five minutes and re-tested motor strength of the Extensor Hallucis Longus EHL Tibialis Anterior TA and Extensor Digitorum Longus EDL muscles manually

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None